Breaking News

Lonza, TRACON Release First 2,000L SUB Batch

Lonza's Singapore site in Tuas will manufacture therapeutic antibody TRC105 for TRACON’s ongoing clinical trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza and TRACON Pharmaceuticals, a clinical-stage biopharmaceutical company focused on novel targeted therapeutics for cancer, have successfully delivered the first 2,000L single-use bioreactor (SUB) batch produced from the recently expanded Lonza Singapore site. The batch was supplied under the strategic manufacturing agreement for TRACON’s therapeutic antibody TRC105.   Lonza performed cell-line development and provided clinical supply for TRC105 at its Slough (UK) site, using the GS ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters